Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
44.84
+5.97 (15.36%)
Nov 6, 2026, 1:10 PM EST - Market open

Edgewise Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
1,130-191.41-158.83-114.36-71.66-43.22
Net Income
1,010-167.8-133.81-100.16-67.64-42.81
Earnings Per Share
8.68-1.63-1.45-1.57-1.26-1.14
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,744530.11470.17318.39351.95280.79
Total Debt
3.383.994.745.414.41-
Net Cash (Debt)
1,741526.12465.43312.98347.54280.79
Net Cash Growth
211.27%13.04%48.71%-9.94%23.77%117.51%
Net Cash Per Share
14.975.115.044.916.487.48

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-201.9-143.82-109.03-91.95-52.64-33.51
Capital Expenditures
-0.38-0.26-1.31-5.75-5.55-0.67
Free Cash Flow
-202.28-144.07-110.34-97.69-58.18-34.18
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.